Date: 2011-09-02

Type of information: Licensing agreement

Compound: GS Gene Expression System™

Company: Oxford BioTherapeutics (UK) Lonza (Switzerland)

Therapeutic area:

Type agreement:


Action mechanism:



Oxford BioTherapeutics Ltd (OBT) and Lonza have signed a non-exclusive license agreement providing OBT with access to Lonza’s GS Gene Expression System™. The agreement covers the research, development and commercial use of the GS System™ by OBT. Licensing of the GS Gene Expression System™ expands OBT’s access to world-class technologies for its maturing pipeline of therapeutic antibodies in oncology, and demonstrates its commitment to strengthening both antibody production and preclinical capabilities.

Financial terms:

The agreement contains standard payments and license fees which have not been disclosed.

Latest news:

Is general: Yes